Zinc Preparation Used in Reference 1
Reference 1 1 specifies that zinc acetate or zinc gluconate lozenges were used at a dose of ≥75 mg/day of elemental zinc, taken within 24 hours of symptom onset and continued throughout the duration of the common cold.
Specific Formulation Details
The guideline clearly states two acceptable zinc salt formulations:
- Zinc acetate lozenges
- Zinc gluconate lozenges
Critical Dosing Parameters
The evidence emphasizes several key implementation details 1:
- Minimum effective dose: ≥75 mg elemental zinc per day
- Timing: Must be initiated within 24 hours of symptom onset
- Duration: Continued throughout the entire cold episode
- Delivery form: Specifically lozenges (not tablets for swallowing)
Clinical Context
This recommendation appears in the European Position Paper on Rhinosinusitis and Nasal Polyps 2020 1, which assigned zinc a Level Ia evidence rating for reducing common cold duration. The guideline notes that when used at this specific dose and formulation, zinc significantly reduces the duration of common cold symptoms.
The lozenge formulation is critical because it allows local contact with oropharyngeal tissues rather than systemic absorption alone. The distinction between zinc acetate and zinc gluconate relates primarily to tolerability rather than efficacy, though both salts are considered effective when delivering the target elemental zinc dose.